GERD Clinical Trial
Official title:
Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs
Verified date | January 2011 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This study was a multicentre, double-blind, randomised, placebo-controlled parallel group study consisting of 4 visits over a period of 6 months. The primary variable was to assess the efficacy of esomeprazole 40 mg orally qd (E40) or esomeprazole 20 mg orally qd (E20) versus placebo orally qd after 6 months of treatment for the prevention of relapse of upper GI symptoms associated with NSAID use, including COX-2 selective NSAIDs, in patients receiving daily NSAID therapy.
Status | Completed |
Enrollment | 334 |
Est. completion date | February 2003 |
Est. primary completion date | February 2003 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Signed informed consent. - Completed the SH-NEN-0001 study with relief of upper GI symptom. Relief is defined as "last 7 days with a diary assessment of None or Minimal, but allowing up to 2 days to be rated as Mild during the 7-day period". - A clinical diagnosis of a chronic condition (e.g., osteoarthritis or rheumatoid arthritis) that requires continuous daily NSAID treatment for at least 6 months. Daily NSAID treatment is defined as taking the prescribed dose for at least 5 of 7 days in any given week and can include COX-2 selective NSAIDs, multiple NSAIDs, and high-dose NSAIDs. - Daily NSAID treatment dose and type: (Must have been stable for at least 9 weeks prior to inclusion and; Are expected to remain stable for the duration of the study. and; Must be administered orally. If more than one type of NSAID treatment is used, at least one type must be administered orally). - Hp negative on Histology performed at baseline endoscopy in the study SHNEN- 0001. Exclusion Criteria: - Discontinuation from study SH-NEN-0001 - Pain, discomfort or burning in the upper abdomen precipitated by exercise or relieved by defecation. - Pain, discomfort or burning in the upper abdomen not associated with the use of NSAIDs, including COX-2 selective NSAIDs. - Pregnancy or lactation. Women of childbearing potential must maintain effective contraception during the study period as judged by the investigator. - Need for continuous concomitant therapy with: (Anticoagulants; Corticosteroids at doses higher than explained under inclusion criterion) |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Belgium | Research Site | Alleur | |
Belgium | Research Site | Ans | |
Belgium | Research Site | Beernem | |
Belgium | Research Site | Betekom | |
Belgium | Research Site | Bottelaere | |
Belgium | Research Site | Braine-L 'Alleud | |
Belgium | Research Site | Buizingen | |
Belgium | Research Site | Duffel | |
Belgium | Research Site | Durnal | |
Belgium | Research Site | Erembodegem | |
Belgium | Research Site | Genk | |
Belgium | Research Site | Gent | |
Belgium | Research Site | Herentals | |
Belgium | Research Site | Lambermont | |
Belgium | Research Site | Leut | |
Belgium | Research Site | Liège | |
Belgium | Research Site | Linkebeek | |
Belgium | Research Site | Maasmechelen | |
Belgium | Research Site | Massemen | |
Belgium | Research Site | Merelbeke | |
Belgium | Research Site | Natoye | |
Belgium | Research Site | Nivelles | |
Belgium | Research Site | Oud-Heverlee | |
Belgium | Research Site | Seraing | |
Belgium | Research Site | Soignies | |
Belgium | Research Site | Vorst (Brussels) | |
Belgium | Research Site | Waremme | |
Belgium | Research Site | Zoersel | |
Belgium | Research Site | Zolder | |
France | Research Site | Albens | |
France | Research Site | Angers | |
France | Research Site | Dambach La Ville | |
France | Research Site | Dommartin-les-touls | |
France | Research Site | Fontaine Les Dijon | |
France | Research Site | Gemenos | |
France | Research Site | Geste | |
France | Research Site | Husseren-wesserling | |
France | Research Site | La Regrip | |
France | Research Site | Le Pian Medoc | |
France | Research Site | Lille | |
France | Research Site | Lyon | |
France | Research Site | Maromme | |
France | Research Site | MONT DE MARSAN Cedex | |
France | Research Site | Montingy Les Metz | |
France | Research Site | Paris Cedex 10 | |
France | Research Site | Saint-ouen | |
France | Research Site | Strasbourg | |
France | Research Site | Tarare | |
Germany | Research Site | Berlin | |
Germany | Research Site | Bernau | |
Germany | Research Site | Bochum | |
Germany | Research Site | Dresden | |
Germany | Research Site | Dresden-Test | |
Germany | Research Site | Erfurt | |
Germany | Research Site | Erlangen | |
Germany | Research Site | Genthin | |
Germany | Research Site | Herne | |
Germany | Research Site | Kelkheim | |
Germany | Research Site | Köln | |
Germany | Research Site | Künzing | |
Germany | Research Site | Lienen | |
Germany | Research Site | Lüdenscheid | |
Germany | Research Site | München | |
Germany | Research Site | Münster | |
Germany | Research Site | Paderborn | |
Germany | Research Site | Passau | |
Germany | Research Site | Potsdam | |
Germany | Research Site | Ratingen | |
Germany | Research Site | Regensburg | |
Germany | Research Site | Ribnitz-Damgarten | |
Germany | Research Site | Saarbrücken | |
Germany | Research Site | Salzgitter | |
Germany | Research Site | Wangen | |
Germany | Research Site | Wiesbaden | |
Germany | Research Site | Wolmirstedt | |
Hungary | Research Site | Békéscsaba | |
Hungary | Research Site | Budapest | |
Hungary | Research Site | Dunaújváros | |
Hungary | Research Site | Szentes | |
Hungary | Research Site | Szombathely | |
Hungary | Research Site | Vác | |
Hungary | Research Site | Veszprém | |
Spain | Research Site | Barcelona | |
Spain | Research Site | Getafe | |
Spain | Research Site | Guadalajara | |
Spain | Research Site | Madrid | |
Spain | Research Site | Mérida | |
Spain | Research Site | Palma de Mallorca | |
Spain | Research Site | San Sebastián(Guipuzcoa) | |
Spain | Research Site | Sevilla | |
Spain | Research Site | Torrelavega | |
Spain | Research Site | Valencia | |
Spain | Research Site | Viladecans | |
Spain | Research Site | Zaragoza | |
United States | Research Site | Anaheim | California |
United States | Research Site | Baltimore | Maryland |
United States | Research Site | Bradenton | Florida |
United States | Research Site | Clearwater | Florida |
United States | Research Site | Conyers | Georgia |
United States | Research Site | Ft. Lauderdale | Florida |
United States | Research Site | Jacksonville | Florida |
United States | Research Site | Newburgh | Indiana |
United States | Research Site | Norfolk | Virginia |
United States | Research Site | Orange | California |
United States | Research Site | San Francisco | California |
United States | Research Site | South Miami | Florida |
United States | Research Site | Tipton | Pennsylvania |
United States | Research Site | Tucson | Arizona |
United States | Research Site | Tulsa | Oklahoma |
United States | Research Site | Virginia Beach | Virginia |
United States | Research Site | West Palm Beach | Florida |
United States | Research Site | Winston-Salem | North Carolina |
United States | Research Site | Zephyr Hills | Florida |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United States, Belgium, France, Germany, Hungary, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the efficacy of esomeprazole 40 mg orally q.d. versus placebo orally q.d. | |||
Primary | and 20 mg q.d. versus placebo orally q.d. through 6 months of treatment for the | |||
Primary | prevention of relapse of upper GI symptom associated with NSAID use in patients | |||
Primary | receiving daily NSAID therapy. | |||
Secondary | To assess the safety and tolerability of esomeprazole 40 mg orally q.d. versus placebo orally q.d. and 20 mg orally q.d. versus placebo orally q.d. when administered for 6 months to patients receiving daily NSAID therapy. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06084572 -
Prospective Evaluation of pH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus
|
||
Completed |
NCT03568825 -
Response Surface Pathway Design With Two Interventional- and One Response Variable in Estimating Minimum Efficacy Dose
|
N/A | |
Recruiting |
NCT04703374 -
A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04120025 -
Effectiveness of Diaphragmatic Breathing on Reflux Symptoms in Outpatients
|
N/A | |
Withdrawn |
NCT04771247 -
Endoscopic Cardiac Band Ligation for the Management of Refractory GERD After Laparoscopic Sleeve Gastrectomy
|
N/A | |
Completed |
NCT02575287 -
Minimal Injuries From Esophagus Detected by Optical Enhancement Systemâ„¢ Associated to Optical Magnification HD Scopes
|
N/A | |
Completed |
NCT01710800 -
Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy
|
N/A | |
Completed |
NCT00287339 -
The Utility of Nexium in Chronic Cough and Reflux Disease
|
Phase 4 | |
Completed |
NCT00287391 -
Sleep Disorders and Gastroesophageal Reflux Disease (GERD)
|
Phase 4 | |
Completed |
NCT00629564 -
An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
|
Phase 4 | |
Completed |
NCT04243668 -
ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA)
|
N/A | |
Completed |
NCT03558477 -
PK/PD Clinical Trial of YYD601 in Healthy Adult Male
|
Phase 1 | |
Recruiting |
NCT05042063 -
Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
|
||
Completed |
NCT05069493 -
Long-term Follow-up After Hiatal Hernia Repair by Tension-free Mesh Closure or Simple Suturing
|
||
Terminated |
NCT04626232 -
Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients
|
N/A | |
Completed |
NCT03238534 -
Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS
|
Phase 4 | |
Recruiting |
NCT05974722 -
Mesh Vs Pledgets for Repair of Paraesophageal Hernia
|
N/A | |
Recruiting |
NCT05781347 -
Stretta Versus Conservative Treatment in Obese and Non-obese
|
N/A | |
Completed |
NCT06141577 -
A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05108038 -
A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects
|
Phase 1 |